Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease

Samuel Golpanian, Ivonne H. Schulman, Ray F. Ebert, Alan W. Heldman, Darcy L. Difede, Phillip C. Yang, Joseph C. Wu, Roberto Bolli, Emerson C. Perin, Lem Moyé, Robert D. Simari, Ariel Wolf, Joshua M. Hare

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.

Original languageEnglish (US)
Pages (from-to)186-191
Number of pages6
JournalStem Cells Translational Medicine
Volume5
Issue number2
DOIs
StatePublished - 2016

Keywords

  • Cardiovascular disease
  • Cell dosage
  • Route of administration
  • Stem cell

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease'. Together they form a unique fingerprint.

  • Cite this